Characterizing the bacteriophage PKp-V1 as a potential treatment for ESBL-producing hypervirulent K1 ST258 isolated from veterinary specimens.

Background And Aim: The dearth of new antibiotics necessitates alternative approaches for managing infections caused by resistant superbugs. This study aimed to evaluate the lytic potential of the purified bacteriophage PKp-V1 against extended-spectrum β-lactamase (ESBL) harboring hypervirulent (hvKp)-K1 recovered from veterinary specimens.

Materials And Methods: A total of 50 samples were collected from various veterinary specimens to isolate , followed by antimicrobial susceptibility testing and molecular detection of various virulence and ESBL genes.

CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.

Background: Activating mutations in the Fms-like tyrosine kinase 3 (FLT3) are among the most prevalent oncogenic mutations in acute myeloid leukaemia. Inhibitors selectively targeting FLT3 kinase have shown promising clinical activity; their success in the clinic, however, has been limited due to the emergence of acquired resistance.

Methods: CCT245718 was identified and characterised as a dual Aurora A/FLT3 inhibitor through cell-based and biochemical assays.